Palatin Technologies (PTN) FCF Margin (2010 - 2026)
Palatin Technologies' (PTN) quarterly FCF Margin came in at 113.64% in Q1 2026, up 97.26% quarter-over-quarter from 4142.55% in Q4 2025.
Analysis
Palatin Technologies (PTN) FCF Margin (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported FCF Margin for 14 consecutive years, with 113.64% the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin changed N/A year-over-year to 113.64%; the trailing twelve-month figure through Mar 2026 stood at 116.35% (up 665364.0% YoY), and the FY2024 full-year result was 701.63%, down 8962.0% from the prior year.
- FCF Margin climbed to 113.64% in Q1 2026 per PTN's latest filing, from 4142.55% in the prior quarter.
- Across five years, FCF Margin topped out at 18.34% in Q3 2025 and bottomed at 4428.05% in Q1 2022.
- Historically, FCF Margin has averaged 1249.19% across 5 years, with a median of 751.44% in 2022.
- The sharpest annual moves came in 2022 and 2024: FCF Margin jumped 1640645 bps in 2022, then plunged 130252 bps in 2024.
- Over 5 years, FCF Margin stood at 954.72% in 2022, then surged by 46 bps to 516.85% in 2023, then plunged by 258 bps to 1850.68% in 2024, then tumbled by 124 bps to 4142.55% in 2025, then soared by 97 bps to 113.64% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 113.64%, 4142.55%, and 18.34% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -18,629.40% |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | -113.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -113.64% |
| Dec 31, 2025 | -4,142.55% |
| Sep 30, 2025 | -18.34% |
| Jun 30, 2024 | -1,850.68% |
| Dec 31, 2023 | -516.85% |
| Sep 30, 2023 | -280.46% |
| Jun 30, 2023 | -548.16% |
| Mar 31, 2023 | -127.56% |
| Dec 31, 2022 | -954.72% |
| Sep 30, 2022 | -1,002.99% |
| Jun 30, 2022 | -1,006.30% |
| Mar 31, 2022 | -4,428.05% |
| Dec 31, 2021 | -3,911.08% |
| Sep 30, 2021 | -163.10% |
| Jun 30, 2021 | -17,412.75% |
| Mar 31, 2021 | -3,955.54% |
| Dec 31, 2020 | -8,794.29% |
| Sep 30, 2020 | 1,321.37% |
| Dec 31, 2019 | -23,883.14% |
| Sep 30, 2019 | 56,248.71% |